StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Analysts at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Alliance Global Partners boosted their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $0.14 on Tuesday. The company has a market cap of $19.22 million, a P/E ratio of 0.00 and a beta of 2.06. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $0.16 and its 200-day moving average is $1.66. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The company had revenue of $2.21 million during the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. Equities research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.